$VistaGen Therapeutics (VTGN.US)$ VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 109.09 percent decrease over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $234.00 thousand which beat the analyst consensus estimate of $180.00 thousand by 30.00 percent. This is a 43.12 percent decrease over sales of $411.40 thousand th...

$VistaGen Therapeutics (VTGN.US)$
Breakthrough Pain Treatment Patent: Vistagen's Non-Opioid AV-101 Shows Promise Against Gabapentin

$VistaGen Therapeutics (VTGN.US)$ Reuters· just
Vistagen Receives U.S. Patent for Av-101 to Treat Neuropathic Pain

$VistaGen Therapeutics (VTGN.US)$
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Wednesday, 5th February at 8:30 am
Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatmen...

$VistaGen Therapeutics (VTGN.US)$ coming?

$VistaGen Therapeutics (VTGN.US)$ Reuters· 1 min ago
Vistagen Announces Positive Results From Exploratory Phase 2a Study of Ph284 in Cancer Cachexia

$VistaGen Therapeutics (VTGN.US)$
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
Tuesday, 14th January at 8:30 am
PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patients
PH284 is the fifth pherine product candidate in Vistagen's neuroscience pipeline with a positive efficacy signal
Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircu...

$VistaGen Therapeutics (VTGN.US)$
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
Friday, 10th January at 8:30 am
All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway
Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in ...

$VistaGen Therapeutics (VTGN.US)$
500k shares buy usd3!!